Pembrolizumab in mycosis fungoides with PD-L1 structural variants-Reference-Cited by-同舟云学术

Pembrolizumab in mycosis fungoides with PD-L1 structural variants

Published:2021-02-03 Issue:3 Volume:5 Page:771-774
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Beygi Sara¹,Fernandez-Pol Sebastian²^ORCID,Duran George¹^ORCID,Wang Erica B.³,Stehr Henning²,Zehnder James L.²,Ramchurren Nirasha⁴,Fling Steven P.⁴^ORCID,Cheever Martin A.⁴^ORCID,Weng Wen-Kai³⁵,Kim Youn H.¹³,Khodadoust Michael S.¹³^ORCID

Affiliation:

1. Division of Medical Oncology, Department of Medicine,

2. Department of Pathology, and

3. Department of Dermatology, Stanford University, Stanford, CA;

4. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and

5. Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA

Abstract

Key Points PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation. PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/5/3/771/1799435/advancesadv2020002371.pdf

Reference19 articles.

1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial;Kim;Lancet Oncol,2018

2. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma;Horwitz;Blood,2012

3. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results;Duvic;J Clin Oncol,2001

4. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma;Whittaker;J Clin Oncol,2010

5. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma;Olsen;J Clin Oncol,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the pharmacological management of cutaneous T-cell lymphoma;Expert Opinion on Pharmacotherapy;2024-05-02

2. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides;Cells;2024-02-27

3. Syndrome de Sézary;Hématologie;2024-01-01

4. PD-1 Overexpression in Sézary Syndrome Is Epigenetically Regulated;Journal of Investigative Dermatology;2023-12

5. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments;Frontiers in Immunology;2023-10-05